Sarcomatoid RCC – molecular features and new opportunities for treatment
Sarcomatoid renal cell carcinoma (RCC) is difficult to treat and [...]
The future of immunotherapy-based combinations for metastatic kidney cancer
The past decade or so has seen the development of [...]
Molecular genetics of renal cell carcinoma
Most renal cell carcinomas (RCC) are diagnosed from studying the [...]
Rational approaches to treatment duration with immunotherapy for kidney cancer
A recent review of the use of immune checkpoint inhibitors [...]
Long term survival after radiofrequency ablation for kidney cancer
A study published in the Journal of Vascular and Interventional [...]
Immunotherapy combinations standard of care for advanced kidney cancer
In 2015, the standard treatment for most patients with advanced [...]
Individualised treatment plans improve outcomes for kidney cancer
Over the past couple of years there have been several [...]
Nivolumab/ipilimumab combination extends treatment-free survival in kidney cancer patients
Immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab have [...]
Predictive biomarkers needed for combination treatments in kidney cancer
In this interview with OncLive, Dr Ulka Vaishampayan from Wayne [...]
PARP inhibitors, vaccines and combination therapies for kidney cancer
In this interview with OncLive, professor Sumanta Kumar Pal from [...]
